The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients

by Melissa A. Jackson, Amanda L. Brown, Jennifer Johnston, Richard Clancy, Iain McGregor, Raimondo Bruno, Nick Lintzeris, Mark Montebello, Jennifer Luksza, Jenny Bowman, Nghi Phung, Dave Allsop, Adrian J. Dunlop
Published 2021-07-01

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial

by Jason Grebely, Phillip Read, Evan B. Cunningham, Martin Weltman, Gail V. Matthews, Adrian Dunlop, Mark Montebello, Marianne Martinello, Rosie Gilliver, Philippa Marks, Tanya L. Applegate, Gregory J. Dore, the DARLO‐C Study Group
Published 2020-06-01

Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol

by Anjali K. Bhardwaj, David J. Allsop, Jan Copeland, Iain S. McGregor, Adrian Dunlop, Marian Shanahan, Raimondo Bruno, Nghi Phung, Mark Montebello, Craig Sadler, Jessica Gugusheff, Melissa Jackson, Jennifer Luksza, Nicholas Lintzeris, Agonist Replacement for Cannabis Dependence (ARCD) study group
Published 2018-05-01

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study

by Adrian Dunlop, Louisa Degenhardt, Michael Farrell, Marian Shanahan, Suzanne Nielsen, Briony Larance, Kari Lancaster, Marianne Byrne, Nicholas Lintzeris, Jason Grebely, Jeyran Shahbazi, Gregory Dore, Robert Ali, Carla Treloar, Stella Nalukwago, Craig Rodgers, Michael McDonough, Jon Cook, Mark Montebello, Michael Aufgang, Robert Weiss, Zoe Griffin
Published 2020-07-01